Chitogenx Inc C.CHGX

Alternate Symbol(s): CHNXF

ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.

CSE:CHGX - Post by User

Chitogenx Inc > Business Update on its Ortho-R Rotator Cuff Program

<< Previous

Bullboard Posts

Next >>

Comment by RockLobster1on Aug 28, 2019 9:51am

184 Views

Post# 30074176

RE:Business Update on its Ortho-R Rotator Cuff Program

RockLobster1 wrote:

MONTREAL, Aug. 14, 2019 /CNW/ (CSE: ORTH) ("Ortho RTi" or the "Company"), an emerging Orthobiologics company, provided today a business update on its Ortho-R rotator cuff program.

Following a successful pre-IND meeting with the Food and Drug Administration ("FDA) in February 2019, the Company is now completing its preparation in order to start its rotator cuff Phase I/II clinical trial. The IND filing is anticipated by fiscal year-end. Ortho RTi started a 6-month pivotal preclinical study in January 2019 to provide the required data and address remaining FDA requirements in order to finalize the Phase I/II protocol. The in-life portion of the 6-month preclinical study as well as data collection have now been successfully completed. Final reporting is expected in the fall of 2019, along with other final IND requirements regarding manufacturing and stability.

"We are pleased to have completed this milestone according to schedule and look forward to updating our shareholders with the study results before year-end." said Claude LeDuc, President and Chief Executive Officer of Ortho RTi. "It is an exciting time for ORTHO RTI, as in parallel to the study, we continue working hard at multiple important deliverables in order to meet our coming IND submission timeline".